0

Explore original, structured summaries for research and education.

Research profile

Tesamorelin(Egrifta SV)

(Egrifta SV)

Tesamorelin(Egrifta SV) is indexed as a GHRH analog research entry. Its current evidence category is (Egrifta SV), and published discussion commonly places it within Growth Hormone, Weight Loss. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.

Growth HormoneWeight Loss

Identity

Molecular Data

Molecular weight
5,135.9 Da
Chain length
44 amino acids
Type
GHRH analog
Reported half-life
26-38 minutes
Amino-acid sequenceHis-Ala-Asp-Gly-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu

Literature map

Research indications

Weight Loss

  • HIV-Associated Lipodystrophymost effective
  • Selective Visceral Fat Targetingmost effective
  • Sustained Fat Losseffective

Metabolic

  • Triglyceride Reductioneffective
  • Cholesterol Profile Improvementeffective
  • NAFLD Treatmenteffective

Body Composition

  • Lean Mass Preservationmoderate
  • IGF-1 Elevationmoderate

Evidence-gated guidance

Dosing Protocols

A medicine-related record exists, but this profile does not yet contain an independently verified, jurisdiction-specific prescribing schedule. Use only the current authorized product label and a licensed clinician’s directions.

Dose
Not established on this profile
Frequency
Not established on this profile
Cycle
Not established on this profile
Storage
Follow the exact supplier or authorized product documentation; requirements vary by formulation
Open peptide calculator →

Combination risks

Interactions

Evidence status

No independently verified interaction table is available here for Tesamorelin(Egrifta SV). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.

Do not infer compatibility

Being listed beside another compound does not mean that combining them is safe or effective.

Evidence-informed overview

What to Expect

Evidence boundary

Research indications describe topics studied in the literature; they do not predict an individual outcome.

Clinical monitoring

Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.

Risk overview

Side Effects & Safety

The safety profile of Tesamorelin(Egrifta SV) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.

Verification

Quality Checklist

  1. Confirm exact chemical identity, sequence, salt form, and concentration.
  2. Require a batch-specific certificate of analysis with named test methods and results.
  3. Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
  4. For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.

Clear answers

Frequently Asked Questions

Is Tesamorelin(Egrifta SV) approved for personal use?

An approved medicine-related record may exist, but approval depends on the exact active ingredient, product, indication, formulation, and country. Check the current local regulator and product label.

Why is no dose listed?

A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.

Do research indications prove effectiveness?

No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.

Source trail

References

  1. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV (LIPO-010)Falutz, J., et al. · New England Journal of Medicine · 2007
  2. Effects of Tesamorelin in HIV-Infected Patients with Abdominal Fat Accumulation: Randomized Placebo-Controlled Trial with Safety Extension (CTR-1011)Falutz, J., et al. · Journal of Acquired Immune Deficiency Syndromes · 2010
  3. Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults with MCI and Healthy Older AdultsBaker, L.D., et al. · Archives of Neurology · 2012
  4. Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV: A Randomised, Double-Blind, Multicentre TrialStanley, T.L., et al. · Lancet HIV · 2019
  5. Body Composition, Hepatic Fat, Metabolic, and Safety Outcomes of Tesamorelin: A Meta-Analysis of Randomized Controlled TrialsElgenidy, A., et al. · HIV Medicine · 2025

View the structural source profile ↗